Kathryn L Pellegrini1,2, Dattatraya Patil1,2, Kristen J S Douglas1,2, Grace Lee1,2, Kathryn Wehrmeyer1,2, Mersiha Torlak1,2, Jeremy Clark3, Colin S Cooper3, Carlos S Moreno2,4,5, Martin G Sanda1,2. 1. Department of Urology, Emory University School of Medicine, Atlanta, Georgia. 2. Winship Cancer Institute, Emory University, Atlanta, Georgia. 3. Norwich Medical School, University of East Anglia, Norwich, UK. 4. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia. 5. Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, Georgia.
Abstract
BACKGROUND: The measurement of gene expression in post-digital rectal examination (DRE) urine specimens provides a non-invasive method to determine a patient's risk of prostate cancer. Many currently available assays use whole urine or cell pellets for the analysis of prostate cancer-associated genes, although the use of extracellular vesicles (EVs) has also recently been of interest. We investigated the expression of prostate-, kidney-, and bladder-specific transcripts and known prostate cancer biomarkers in urine EVs. METHODS: Cell pellets and EVs were recovered from post-DRE urine specimens, with the total RNA yield and quality determined by Bioanalyzer. The levels of prostate, kidney, and bladder-associated transcripts in EVs were assessed by TaqMan qPCR and targeted sequencing. RESULTS: RNA was more consistently recovered from the urine EV specimens, with over 80% of the patients demonstrating higher RNA yields in the EV fraction as compared to urine cell pellets. The median EV RNA yield of 36.4 ng was significantly higher than the median urine cell pellet RNA yield of 4.8 ng. Analysis of the post-DRE urine EVs indicated that prostate-specific transcripts were more abundant than kidney- or bladder-specific transcripts. Additionally, patients with prostate cancer had significantly higher levels of the prostate cancer-associated genes PCA3 and ERG. CONCLUSIONS: Post-DRE urine EVs are a viable source of prostate-derived RNAs for biomarker discovery and prostate cancer status can be distinguished from analysis of these specimens. Continued analysis of urine EVs offers the potential discovery of novel biomarkers for pre-biopsy prostate cancer detection.
BACKGROUND: The measurement of gene expression in post-digital rectal examination (DRE) urine specimens provides a non-invasive method to determine a patient's risk of prostate cancer. Many currently available assays use whole urine or cell pellets for the analysis of prostate cancer-associated genes, although the use of extracellular vesicles (EVs) has also recently been of interest. We investigated the expression of prostate-, kidney-, and bladder-specific transcripts and known prostate cancer biomarkers in urine EVs. METHODS: Cell pellets and EVs were recovered from post-DRE urine specimens, with the total RNA yield and quality determined by Bioanalyzer. The levels of prostate, kidney, and bladder-associated transcripts in EVs were assessed by TaqMan qPCR and targeted sequencing. RESULTS: RNA was more consistently recovered from the urine EV specimens, with over 80% of the patients demonstrating higher RNA yields in the EV fraction as compared to urine cell pellets. The median EV RNA yield of 36.4 ng was significantly higher than the median urine cell pellet RNA yield of 4.8 ng. Analysis of the post-DRE urine EVs indicated that prostate-specific transcripts were more abundant than kidney- or bladder-specific transcripts. Additionally, patients with prostate cancer had significantly higher levels of the prostate cancer-associated genes PCA3 and ERG. CONCLUSIONS: Post-DRE urine EVs are a viable source of prostate-derived RNAs for biomarker discovery and prostate cancer status can be distinguished from analysis of these specimens. Continued analysis of urine EVs offers the potential discovery of novel biomarkers for pre-biopsy prostate cancer detection.
Authors: Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone Journal: Lancet Oncol Date: 2011-03 Impact factor: 41.316
Authors: Glenn K Fu; Weihong Xu; Julie Wilhelmy; Michael N Mindrinos; Ronald W Davis; Wenzhong Xiao; Stephen P A Fodor Journal: Proc Natl Acad Sci U S A Date: 2014-01-21 Impact factor: 11.205
Authors: John T Wei; Ziding Feng; Alan W Partin; Elissa Brown; Ian Thompson; Lori Sokoll; Daniel W Chan; Yair Lotan; Adam S Kibel; J Erik Busby; Mohamed Bidair; Daniel W Lin; Samir S Taneja; Rosalia Viterbo; Aron Y Joon; Jackie Dahlgren; Jacob Kagan; Sudhir Srivastava; Martin G Sanda Journal: J Clin Oncol Date: 2014-11-10 Impact factor: 44.544
Authors: M J Bussemakers; A van Bokhoven; G W Verhaegh; F P Smit; H F Karthaus; J A Schalken; F M Debruyne; N Ru; W B Isaacs Journal: Cancer Res Date: 1999-12-01 Impact factor: 12.701
Authors: Nicholas Erho; Anamaria Crisan; Ismael A Vergara; Anirban P Mitra; Mercedeh Ghadessi; Christine Buerki; Eric J Bergstralh; Thomas Kollmeyer; Stephanie Fink; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Karla V Ballman; Timothy J Triche; Peter C Black; R Jeffrey Karnes; George Klee; Elai Davicioni; Robert B Jenkins Journal: PLoS One Date: 2013-06-24 Impact factor: 3.240
Authors: J Nilsson; J Skog; A Nordstrand; V Baranov; L Mincheva-Nilsson; X O Breakefield; A Widmark Journal: Br J Cancer Date: 2009-04-28 Impact factor: 7.640
Authors: Esther Campos-Fernández; Letícia S Barcelos; Aline Gomes de Souza; Luiz R Goulart; Vivian Alonso-Goulart Journal: Am J Cancer Res Date: 2019-07-01 Impact factor: 6.166
Authors: Amanda Khoo; Lydia Y Liu; Julius O Nyalwidhe; O John Semmes; Danny Vesprini; Michelle R Downes; Paul C Boutros; Stanley K Liu; Thomas Kislinger Journal: Nat Rev Urol Date: 2021-08-27 Impact factor: 14.432
Authors: Irene Casanova-Salas; Alejandro Athie; Paul C Boutros; Marzia Del Re; David T Miyamoto; Kenneth J Pienta; Edwin M Posadas; Adam G Sowalsky; Arnulf Stenzl; Alexander W Wyatt; Joaquin Mateo Journal: Eur Urol Date: 2021-01-07 Impact factor: 24.267
Authors: Michael A Liss; Robin J Leach; Martin G Sanda; Oliver J Semmes Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-10-22 Impact factor: 4.254
Authors: Shea P Connell; Marcel Hanna; Frank McCarthy; Rachel Hurst; Martyn Webb; Helen Curley; Helen Walker; Rob Mills; Richard Y Ball; Martin G Sanda; Kathryn L Pellegrini; Dattatraya Patil; Antoinette S Perry; Jack Schalken; Hardev Pandha; Hayley Whitaker; Nening Dennis; Christine Stuttle; Ian G Mills; Ingrid Guldvik; Chris Parker; Daniel S Brewer; Colin S Cooper; Jeremy Clark Journal: BJU Int Date: 2019-05-20 Impact factor: 5.588